Roivant launches lung-focused Respivant with phase 2 IPF drug

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Sep 18, 2018 at 10:22 AM.

  1. #1 cafead, Sep 18, 2018 at 10:22 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via Roivant Sciences’ spinout machine keeps turning, with the launch of the lung-disease focused Respivant Sciences, a company built around an inhaled drug for treating chronic cough in patients with idiopathic pulmonary fibrosis.

    article source
     
    Quote

Reply to Thread